Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ATXS 
Astria Therapeutics Inc (ATXS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/29/2025: ATXS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $29.33
1 Year Target Price $29.33
| 7 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 107.65% | Avg. Invested days 66 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 348.77M USD | Price to earnings Ratio - | 1Y Target Price 29.33 |
Price to earnings Ratio - | 1Y Target Price 29.33 | ||
Volume (30-day avg) 9 | Beta 0.48 | 52 Weeks Range 3.56 - 12.92 | Updated Date 08/30/2025 |
52 Weeks Range 3.56 - 12.92 | Updated Date 08/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.02 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.49 | Actual -0.57 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -25.28% | Return on Equity (TTM) -38.49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 189679644 | Price to Sales(TTM) - |
Enterprise Value 189679644 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -7.57 | Shares Outstanding 56434900 | Shares Floating 34521225 |
Shares Outstanding 56434900 | Shares Floating 34521225 | ||
Percent Insiders 0.49 | Percent Institutions 102.55 |
Upturn AI SWOT
Astria Therapeutics Inc
Company Overview
History and Background
Astria Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and niche allergic and immunological diseases. Founded in 2019 and formerly known as Integral Molecular, the company has evolved through strategic acquisitions and a focus on hereditary angioedema (HAE).
Core Business Areas
- Hereditary Angioedema (HAE): Developing STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, for the prophylactic treatment of HAE. This is their primary focus.
Leadership and Structure
Perry Sternberg is the President and CEO. The company has a typical biopharmaceutical organizational structure with departments dedicated to research, clinical development, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- STAR-0215: A monoclonal antibody inhibitor of plasma kallikrein in development for the prophylactic treatment of hereditary angioedema (HAE). Currently in clinical trials. Competitors include Takeda (TAKYY) with Takhzyro and BioCryst Pharmaceuticals (BCRX) with Orladeyo.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, with a focus on developing novel therapies for unmet medical needs, particularly in rare diseases.
Positioning
Astria Therapeutics is positioning itself as a key player in the HAE market with STAR-0215, potentially offering improved dosing convenience and efficacy compared to existing treatments.
Total Addressable Market (TAM)
The global HAE market is estimated to be several billion dollars annually. Astria is positioned to capture a portion of this TAM with a potentially superior product.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach with STAR-0215
- Strong intellectual property position
- Experienced management team
- Focus on a well-defined market with unmet needs
Weaknesses
- Dependence on the success of STAR-0215
- Early-stage company with limited commercial infrastructure
- High cash burn rate
- Clinical trial risk
Opportunities
- Positive clinical trial results for STAR-0215
- Expansion into other rare disease indications
- Partnerships with larger pharmaceutical companies
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Competition from existing and emerging HAE therapies
- Regulatory hurdles
- Patent challenges
- Economic downturn affecting funding
Competitors and Market Share
Key Competitors
- TAKYY
- BCRX
Competitive Landscape
Astria faces competition from established players like Takeda and BioCryst, but STAR-0215 could potentially offer a more convenient dosing schedule or superior efficacy.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by expansion of R&D activities and clinical development programs.
Future Projections: Future growth is contingent on the successful development and commercialization of STAR-0215. Analyst estimates vary based on perceived probability of success.
Recent Initiatives: Recent initiatives include advancing STAR-0215 through clinical trials and exploring potential partnerships.
Summary
Astria Therapeutics is a high-risk, high-reward biopharmaceutical company focused on developing STAR-0215 for HAE. Its success hinges on positive clinical trial results and regulatory approval. While it faces competition from established players, STAR-0215's potential profile could give it a competitive edge. The company needs to manage its cash burn carefully as it advances its clinical programs.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a financial advisor. Market share data is approximate and based on available estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Astria Therapeutics Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2015-06-25 | Co-Founder, CEO, President & Director Ms. Jill C. Milne Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 78 | Website https://www.astriatx.com |
Full time employees 78 | Website https://www.astriatx.com | ||
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.